Richard Maziarz, MD, provides an overview of the drug ruxolitinib, which was recently approved for use in steroid-refractory acute GVHD (graft-vs-host disease). He leads a discussion on the results of REACH-1 and REACH-2 and the experiences of the other panelists in using this drug.
Read More
Richard Maziarz, MD, highlights the fact that graft-vs-host disease (GVHD) is a T-cell disease and then outlines qualitative and quantitative mechanisms that are used to prophylactically target the alloreactive T-cell population. A calcineurin inhibitor combined with methotrexate is the currently accepted standard of care for GVHD prophylaxis. Panelists weigh in on the use of post-transplant cyclophosphamide (PTCy) for prevention of GVHD.
Read More
Immunopathology and GVHD Incidence
July 9th 2021Yi-Bin Chen , MD, provides an overview of how the landscape graft-vs-host disease (GVHD) has evolved over the past 3 decades. Corey Cutler, MD, PhD, FRCPC, provides an overview of GVHD biology. Potential risk factors for development of acute and chronic GVHD are discussed.
Read More
Dr. Maziarz on Sustained Responses With Tisagenlecleucel in DLBCL
February 20th 2019Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses sustained responses with tisagenlecleucel in the treatment of patients with diffuse large B-cell lymphoma.
Read More
Dr. Maziarz Discusses Promise of Tisagenlecleucel in DLBCL
February 2nd 2019Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses the promise of tisagenlecleucel in the treatment of patients with diffuse large B-cell lymphoma.
Read More